Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIANA-NEXT: Dotinurad vs Febuxostat in Hyperuricemia with Hypertension
NCT06834230Phase 4Recruiting
- Sponsor
- Saga University
- Start
- Mar 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dotinurad in hyperuricemia (2 arms), sponsored by Saga University. Primary endpoint: Change in cardio-ankle vascular index at 24 weeks. Started Mar 2025; status: recruiting.
02
Drugs
dotinurad
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT06834230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834230.